BioXpress Therapeutics SA
http://www.bioxpress.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioXpress Therapeutics SA
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
BioXpress And Abzena Partner On Biosimilar Development
BioXpress Therapeutics and Abzena, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers. The companies plan to offer a “flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”
Roche’s Actemra Scores New Indication In Rare Autoimmune Disease
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice